Balamucki Christopher J, DeJesus Reordan, Galloway Thomas J, Mancuso Anthony A, Amdur Robert J, Morris Christopher G, Kirwan Jessica M, Mendenhall William M
*Departments of Radiation Oncology †Radiology, University of Florida College of Medicine, Gainesville, FL ‡Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.
Am J Clin Oncol. 2015 Jun;38(3):248-51. doi: 10.1097/COC.0b013e3182940ddf.
Update our experience using radiotherapy (RT) for head-and-neck squamous or basal cell carcinoma with clinical perineural invasion (PNI) and correlate radiographic findings with outcomes.
We treated 65 patients with cT4N0 head-and-neck skin cancers with clinical PNI from 1965 to 2009 (N0 disease, 59; N1 disease, 6). Treatment included RT alone (N=18), RT with concurrent chemotherapy (N=14), surgery and postoperative RT (N=26), or postoperative RT with concurrent chemotherapy (N=5), and preoperative RT and surgery (N=2). Patients were stratified by imaging-negative disease (N=11), minimal or moderate peripheral disease (N=18), and macroscopic and/or central disease (N=36). Median RT dose was 72.6 Gy (50.4 to 79.2 Gy). Median follow-up overall and for living patients was 5.4 and 11.6 years, respectively.
Five-year outcomes for imaging-negative disease versus minimal/moderate peripheral disease versus macroscopic/central disease were: local control, 81% versus 60% versus 47% (P=0.23); local-regional control, 80% versus 54% versus 47% (P=0.22); neck control, 100% versus 89% versus 93% (P=0.45); and distant metastasis-free survival, 89% versus 100% versus 93% (P=0.57), respectively. Five-year survival rates for imaging-negative disease versus minimal/moderate peripheral disease versus macroscopic/central disease were: overall survival, 82% versus 50% versus 52% (P=0.26), and cause-specific survival, 100% versus 58% versus 65% (P=0.08). Twenty-two (34%) patients had 1 or more severe (grade ≥3) late complications.
There is a nonsignificant trend towards improved local control for imaging-negative patients and patients with minimal/moderate peripheral disease compared with macroscopic/central disease. Although survival appears better for imaging-negative patients, extent of imaging-positive PNI did not impact overall or cause-specific survival.
更新我们使用放射治疗(RT)治疗头颈部鳞状或基底细胞癌伴临床神经周围浸润(PNI)的经验,并将影像学表现与预后相关联。
1965年至2009年,我们治疗了65例cT4N0头颈部皮肤癌伴临床PNI的患者(N0期疾病5�例,N1期疾病6例)。治疗方法包括单纯放疗(N = 18)、放疗联合同步化疗(N = 14)、手术及术后放疗(N = 26)、术后放疗联合同步化疗(N = 5)以及术前放疗及手术(N = 2)。患者按影像学阴性疾病(N = 11)、轻度或中度周围疾病(N = 18)以及肉眼可见和/或中央疾病(N = 36)进行分层。放疗中位剂量为72.6 Gy(50.4至79.2 Gy)。总体及存活患者的中位随访时间分别为5.4年和11.6年。
影像学阴性疾病、轻度/中度周围疾病、肉眼可见/中央疾病的5年预后情况如下:局部控制率分别为81% vs 60% vs 47%(P = 0.23);局部区域控制率分别为80% vs 54% vs 47%(P = 0.22);颈部控制率分别为100% vs 89% vs 93%(P = 0.45);远处无转移生存率分别为89% vs 100% vs 93%(P = 0.57)。影像学阴性疾病、轻度/中度周围疾病、肉眼可见/中央疾病的5年生存率如下:总生存率分别为82% vs 50% vs 52%(P = 0.26),病因特异性生存率分别为100% vs 58% vs 65%(P = 0.08)。22例(34%)患者出现1种或更多严重(≥3级)晚期并发症。
与肉眼可见/中央疾病相比,影像学阴性患者和轻度/中度周围疾病患者的局部控制有改善的趋势,但无统计学意义。尽管影像学阴性患者的生存率似乎更高,但影像学阳性PNI的范围并未影响总生存率或病因特异性生存率。